Диссертация (1154755), страница 16
Текст из файла (страница 16)
Effect of statins onatrial fibrillation: collaborative meta-analysis of published and unpublishedevidence from randomised controlled trials. BMJ. 2011; 342: d1250.109.Raju SB, Varghese K, Madhu K. Management of statinintolerance. Indian J. Endocrinol. Metab. 2013; 17: 977–982.110.Rannanheimo PK, Tiittanen P, Hartikainen J, et al. Impact ofstatin adherence on cardiovascular morbidity and all cause mortality in the110primary prevention of cardiovascular disease: a population based cohort studyin Finland.
Value Health. 2015; 18: 896–905.111.Reiner Ž, Catapano AL, De Backer G, et al. ESC/EASGuidelines for the management of dyslipidaemias. Eur Heart J. 2011; 32: 17691818.112.Richardson K, Schoen M, French B, et al. Statins and cognitivefunction: a systematic review. Ann Intern Med. 2013;159:688-697.113.Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascularbenefits and diabetes risks of statin therapy in primary prevention: an analysisfrom the JUPITER trial.
Lancet 2012; 380: 565-571.114.Rojas-Fernandes CH, Goldstein LB, Levey AI, et al. Anassessment by the Statin Cognitive Safety Task Force: 2014 update. J ClinLipidol 2014; 8: S5-S16.115.Rosenson RS, Baker SK, Jacobson TA, et al. An assessment bythe Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014; 8(3Suppl): S58-71.116.Rosenson RS. Current overview of statin-induced myopathy.Am J Med. 2004;116(6): 408-416.117.Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes instatin treatment trials: a meta-analysis.
Arch Intern Med 1999; 159:1793–1802.118.Santos RD, Waters DD, Tarasenko L, et al. A comparison ofnon-HDL and LDL cholesterol goal attainment in a large, multinational patientpopulation. Atherosclerosis. 2012; 224(1): 150-153.119.Sathasivam S, Lecky B. Statin induced myopathy. BMJ. 2008;337: a2286.120.Sathasivam S. Statin induced myotoxicity. Eur J InternMed. 2012; 23(4): 317-324.121.Sattar N, Preiss D, Murray HM, et al.
Statins and risk ofincident diabetes: a collaborative meta-analysis of randomised statin trials.Lancet. 2010; 375(9716): 735-742.111122.Scott HD, Laake K. Statins for the prevention of Alzheimer'sdisease. Cochrane Database Syst Rev. 2001; 4: CD003160.123.INCIDENCESeverOFHYPERTENSIVEP, Gupta A, Thompson D, et al. THE TRUESTATINPATIENTS-RELATEDREVEALEDADVERSEBYEVENTSINCOMPARISONOFBLINDED AND UN-BLINDED USE OF STATIN IN THE ANGLOSCANDINAVIAN CARDIAC OUTCOMES TRIAL (ASCOT). J Hypertens.2016; 34 Suppl 1 - ISH 2016 Abstract Book: e547-e548.124.Shaw SM, Fildes JE, Yonan N, et al. Pleiotropic effects andcholesterol-lowering therapy. Cardiology.
2009; 112: 4–12.125.Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in ElderlyIndividuals at Risk of Vascular Disease (PROSPER): a randomised controlledtrial. Lancet 2002; 60: 1623.30.126.Silva MA, Swanson AC, Gandhi PJ, et al.Statin-relatedadverse events: a meta-analysis. Clin Ther. 2006; 28(1): 26-35.127.Simpson RJ, Mendys P.
The effects of adherence andpersistence on clinical outcomes in patients treated with statins: a systematicreview. J Clin Lipidology. 2010; 4: 462-71.128.Smeeth L, Douglas I, Hall AJ, et al. Effect of statins on a widerange of health outcomes: a cohort study validated by comparison withrandomized trials. Br J Clin Pharmacol. 2009; 67(1): 99-109.129.Stach K, Nguyen XD, Lang S, et al.
Simvastatin andatorvastatin attenuate VCAM-1 and uPAR expression on human endothelialcells and platelet surface expression of CD40 ligand. Cardiol J 2012;19(1):2028.130.UpdateStatins: risk of hyperglycaemia and diabetes. Drug SafetyJanuary2012.5:A2(http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/con140667).131.Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013ACC/AHA guideline on the treatment of blood cholesterol to reduce112atherosclerotic cardiovascular risk in adults: a report of the American CollegeofCardiology/AmericanHeartAssociationTaskForceonPracticeGuidelines. Circulation. 2014; 129: S1–S45.132.Stroes ES, Thompson PD, Corsini A, et al.
Statin-associatedmuscle symptoms: impact on statin therapy-European Atherosclerosis SocietyConsensus Panel Statement on Assessment, Aetiology and Management. EurHeart J. 2015; 36(17): 1012-22.133.Summers MJ, Oliver KR, Coombes JS, et al. Effect ofatorvastatin on cognitive function in patients from the Lipid Lowering andOnset of Renal Disease (LORD) trial. Pharmacotherapy 2007; 27(2): 183–90134.Swiger KJ, Manalac RJ, Blumenthal RS, et al.
Statins andCognition: A Systematic Review and Meta-analysis of Short- and Long-termCognitive Effects. Mayo Clin Proc 2013; 88(11): 1213-1221.135.Szwast SJ, Hendrie HC, Lane KA, et al. Association of statinuse with cognitive decline in elderly African Americans. Neurology. 2007;69(19): 1873–1880.136.Taylor F, Huffman MD, Macedo AF, et al. Statins for theprimary prevention of cardiovascular disease. Cochrane Database Syst Rev.2013; 1: CD004816.137.CardiovascularThavendiranathan P,DiseaseswithBagaiA.PrimaryStatinTherapy.
ArchPreventionInternofMed2006; 166: 2307-2313138.Tobert JA, Newman CB. The nocebo effect in the context ofstatin intolerance. J Clin Lipidol. 2016;10(4): 739-747.139.TokgözoğluL, ÖzdemirR, AltındağR, etal.Patientcharacteristics and statin discontinuation-related factors during treatment ofhypercholesterolemia: an observational non-interventional study in patientswith statin discontinuation (STAY study). Turk Kardiyol Dern Ars. 2016;44(1): 53-64.113140.Tong L, Hu H, Zhang S, et al.
Statin Withdrawal Beyond AcutePhase Affected Outcome of Thrombolytic Stroke Patients. Medicine. 2015;94(17): e779.141.Trompet S, van Vliet P, de Craen AJ, et al. Pravastatin andcognitive function in the elderly. Results of the PROSPER study. J Neurol2010; 257(1): 85–90.142.Turin A, Pandit J, Stone NJ. Statins and Nonadherence: ShouldWe RELATE Better? J Cardiovasc Pharmacol Ther. 2015; 20(5): 447-56.143.US Food and Drug Administration.
FDA Drug SafetyCommunication: Important safety label changes to cholesterol-lowering statindrugs2012.http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm.Датапоследнего обновления: January 8 2016.144.van der Meij E, Koning GG, Vriens PW,et al. A ClinicalEvaluation of Statin Pleiotropy: Statins Selectively and Dose- DependentlyReduce Vascular Inflammation. PLoS ONE. 2013; 8(1): e53882.145.Virani SS, Woodard LD, Akeroyd JM, Ramsey DJ, et al. Is highintensity statin therapy associated with lower statin adherence compared withlow to moderate intensity statin therapy? Implications of the 2013 AmericanCollege of Cardiology/American Heart Association cholesterol managementguidelines.
Clin Cardiol. 2014; 37(11): 653–9.146.Wang J, Xiao Y, Luo M, et al. Statins for multiple sclerosis.Cochrane Database Syst Rev. 2011; 12: CD008386.147.Waters DD, Guyton JR, Herrington DM, et al; for the TNTSteering Committee Members and Investigators. Treating to New Targets(TNT) Study: Does lowering low-density lipoprotein cholesterol levels belowcurrently recommended guidelines yield incremental clinical benefit? Am JCardiol. 2004; 93: 154-158.148.Waters DD, Brotons C, Chiang CW, et al.
Lipid TreatmentAssessment Project 2: a multinational survey to evaluate the proportion of114patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120: 28-34.149.Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onsetdiabetes in patients treated with atorvastatin: results from 3 large randomizedclinical trials.
J Am Coll Cardiol. 2011; 57(14): 1535-1545.150.While A, Keen L. The effects of statins on mood: a review ofthe literature. Eur J Cardiovasc Nurs 2012; 11: 85–96.151.Wilt TJ, Bloomfield HE, MacDonald R et al. Effectiveness ofstatin therapy in adults with coronary heart disease. Arch Intern Med. 2004;164: 1427-1436.152.World Health Organization (WHO). Cardiovascular diseases(CVDs) Fact Sheet No. 317. Geneva, Switzerland: WHO; 2011.http://www.who.int/mediacentre/factsheets/fs317/en/print.html. Accessed April13, 2011.153.Yang CC, Jick SS, Jick H.
Lipid-Lowering Drugs and the Riskof Depression and Suicidal Behavior. Arch Intern Med. 2003; 163(16):19261932.154.You H, Lu W, Zhao S, et al. The relationship between statinsand depression: a review of the literature. Expert Opin Pharmacother 2013;14:1467–1476.155.Yu BL, Zhao SP, Peng DQ, et al. A comparison of non-HDLand LDL cholesterol goal attainment in the CHILLAS trial.
Int J Cardiol. 2013;168(4): 4340-4342.156.Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering inintermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374: 2021–31.157.Zhao S, Wang Y, Mu Y, et al. Prevalence of dyslipidaemia inpatients treated with lipid-lowering agents in China: results of theDYSlipidemia International Study (DYSIS). Atherosclerosis. 2014; 235(2):463e9.115158.Zhou Q, Liao JK. Pleiotropic effects of statins. - Basic researchand clinical perspectives. Circ J. 2010; 74: 818–26.159.apolipoproteinZou Y, Hu D, Yang X, et al. Relationships amongA1genepolymorphisms,lipidlevelsandcoronaryatherosclerosis disease .
Chinese Medical Journal. 2003; 116 (5): 665–668..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
